Silver(I) and Copper(I) Cocatalyzed Tandem Reaction of 2‑Alkynylbenzaldoximes with Aldehydes or Alcohols: Approach to 4‑Carboxylated Isoquinolines

A novel and efficient route for the preparation of 4-carboxylated isoquinolines via a Ag­(I) and Cu­(I) cocatalyzed tandem reaction of 2-alkynylbenzaldoximes with aldehydes or alcohols in moderate to good yields is described. The reaction proceeds smoothly to produce C–N and C–O bonds in a one-pot procedure with structural complexity and molecular diversity

A Copper-Catalyzed Three-Component Reaction of Tri­ethoxy­silanes, Sulfur Dioxide, and Hydrazines

A three-component reaction of triethoxysilanes, sulfur dioxide, and hydrazines catalyzed by copper­(II) acetate is reported, leading to <i>N</i>-amino­sulfona­mides in good yields. Not only triethoxy­(aryl)­silanes but also triethoxy­(alkyl)­silanes are compatible during the process of insertion of sulfur dioxide. Additionally, diethoxy­diaryl­silanes are suitable under the conditions as well

Table1_Curative effect of anti-fibrosis Chinese patent medicines combined with ursodeoxycholic acid for primary biliary cholangitis: A systematic review and meta-analysis.DOC

Objective: To delineate the curative effect and safety of anti-fibrosis Chinese patent medicines (CPMs) combined with ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC).Methods: A literature search was conducted using PubMed, Web of Science, Embase, Cochrane Library, Wanfang database, VIP database, China Biology Medicine Database, and Chinese National Knowledge Infrastructure from their inception until August 2022. Randomized controlled trials (RCTs) of the treatment of PBC with anti-fibrotic CPMs were collected. The eligibility of the publications was assessed using the Cochrane risk-of-bias tool. The evaluation indicators were the clinical efficacy rate, liver fibrosis, liver function, immune function, and symptom score. Meta-analysis and subgroup analysis were conducted to evaluate the effectiveness of anti-fibrosis CPMs. Risk ratio (RR) was used to assess dichotomous variables, and continuous variables with a 95% confidence interval were calculated using mean difference.Results: Twenty-two RCTs including 1,725 patients were selected. The findings demonstrated that anti-fibrotic CPMs combined with UDCA improved the efficacy rate, liver function, liver fibrosis, immunological indicators, and clinical symptoms compared with UDCA alone (all p Conclusion: This study demonstrates that the combination of anti-fibrotic CPMs and UDCA can improve both clinical symptoms and outcomes. Nevertheless, more high-quality RCTs are needed to assess the effectiveness of anti-fibrosis CPMs for PBC.</p

Hyperactivation of peripheral CD4⁺ and CD8⁺ T cells in patients with HBV-PLC.

<p>Percentages of HLA-DR -expressed cells (HLA-DR %) among the CD4^<b>+</b> T cells (A) and CD8^<b>+</b> T cells (B) of the peripheral blood were compared between the patients with CHB, those with HBV-LC and those with HBV-PLC. p<0.05 was considered statistically significant.</p

Patient basic characteristics.

<p>Patient basic characteristics.</p

Decreased peripheral recent thymic output in patients with HBV-PLC.

<p>Percentages of CD31⁺ -expressed cells (CD31%) among the CD45RA⁺CD4⁺ T cells (A) and CD45RA⁺CD8⁺ T cells (B) of the peripheral blood were compared between the patients with CHB, those with HBV-LC and those with HBV-PLC. p<0.05 was considered statistically significant.</p

Elevated NLR in patients with HBV-PLC.

<p>NLR (A), percentage (B) and concentration (C) of peripheral blood neutrophils, and percentage (D) and concentration (E) of peripheral blood lymphocytes were compared between patients with CHB, those with HBV-LC and those with HBV-PLC. In addition, NLR (F), percentage (G) and concentration (H) of peripheral neutrophils, and percentage (I) and concentration (J) of peripheral lymphocytes were compared between patients with Okuda I, II and III HBV-LC. p<0.05 was considered statistically significant. abs cnt: absolute count.</p

Decreased peripheral lymphocyte subpopulations in patients with HBV-PLC.

<p>The concentrations of the peripheral blood T lymphocytes (A), NK cells (B), B cells (C), CD4⁺ T cells (D), CD8⁺ T cells (E) were compared between patients with CHB, those with HBV-LC and those with HBV-PLC. p<0.05 was considered statistically significant. abs cnt: absolute count.</p

Data_Sheet_1_Prognosis prediction performs better in patients with non-cirrhosis hepatitis B virus-related acute-on-chronic liver failure than those with cirrhosis.docx

BackgroundThe accurate prediction of the outcome of hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is impeded by population heterogeneity. The study aimed to assess the impact of underlying cirrhosis on the performance of clinical prediction models (CPMs).MethodsUsing data from two multicenter, prospective cohorts of patients with HBV-ACLF, the discrimination, calibration, and clinical benefit were assessed for CPMs predicting 28-day and 90-day outcomes in patients with cirrhosis and those without, respectively.ResultsA total of 919 patients with HBV-ACLF were identified by Chinese Group on the Study of Severe Hepatitis B (COSSH) criteria, including 675 with cirrhosis and 244 without. COSSH-ACLF IIs, COSSH-ACLFs, Chronic Liver Failure-Consortium Acute-on-Chronic Liver Failure score (CLIF-C ACLFs), Tongji Prognostic Predictor Model score (TPPMs), Model for End-Stage Liver Disease score (MELDs), and MELD-Sodium score (MELD-Nas) were all strong predictors of short-term mortality in patients with HBV-ACLF. In contrast to a high model discriminative capacity in ACLF without cirrhosis, each prognostic model represents a marked decline of C-index, net reclassification index (NRI), and integrated discrimination improvement (IDI) in predicting either 28-day or 90-day prognosis of patients with cirrhosis. The hazard analysis identified largely overlapping risk factors of poor outcomes in both subgroups, while serum bilirubin was specifically associated with short-term mortality in patients with cirrhosis and blood urea nitrogen in patients without cirrhosis. A subgroup analysis in patients with cirrhosis showed a decline of discrimination of CPMS in those with ascites or infections compared to that in those without.ConclusionPredicting the short-term outcome of HBV-ACLF by CPMs is optimal in patients without cirrhosis but limited in those with cirrhosis, at least partially due to the complicated ascites or infections.</p